Sinclair Pharma PLC (LON:SPH) had its target price decreased by equities researchers at N+1 Singer from GBX 42 ($0.54) to GBX 37 ($0.48) in a note issued to investors on Wednesday, April 19th. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. N+1 Singer’s price objective indicates a potential upside of 8.82% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on the company. Peel Hunt reiterated a “buy” rating and issued a GBX 68 ($0.88) target price on shares of Sinclair Pharma PLC in a research note on Thursday, January 5th. Jefferies Group LLC restated a “buy” rating and set a GBX 55 ($0.71) price objective on shares of Sinclair Pharma PLC in a research note on Wednesday, March 22nd. Numis Securities Ltd restated a “hold” rating and set a GBX 35 ($0.45) price objective on shares of Sinclair Pharma PLC in a research note on Tuesday, April 4th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 71 ($0.92) price objective on shares of Sinclair Pharma PLC in a research note on Tuesday, April 4th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of GBX 54 ($0.70).
Sinclair Pharma PLC (LON:SPH) remained flat at GBX 34.00 during midday trading on Wednesday. The company had a trading volume of 9,259,710 shares. Sinclair Pharma PLC has a 52 week low of GBX 26.00 and a 52 week high of GBX 36.75. The company’s 50-day moving average is GBX 33.04 and its 200-day moving average is GBX 32.09. The stock’s market cap is GBX 170.75 million.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/05/20/sinclair-pharma-plc-sph-price-target-cut-to-gbx-37-updated-updated-updated.html.
Sinclair Pharma PLC Company Profile
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.